methotrexate indications/contra

Stem definitionDrug idCAS RN
folic acid analogues 1751 59-05-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • methotrexate
  • methotrexate sodium
  • amethopterin
  • amethopterine
  • L-Amethopterin
  • ledertrexate
  • metatrexan
  • methoxtrexate
  • methylaminopterin
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
  • Molecular weight: 454.45
  • Formula: C20H22N8O5
  • CLOGP: -0.53
  • LIPINSKI: 1
  • HAC: 13
  • HDO: 5
  • TPSA: 210.54
  • ALOGS: -3.42
  • ROTB: 9

Drug dosage:

DoseUnitRoute
2.50 mg O
2.50 mg P

Approvals:

DateAgencyCompanyOrphan
Dec. 7, 1953 FDA DAVA PHARMS INC

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 11327.76 19.28 4992 36105 111098 3233664
Rheumatoid arthritis 5625.88 19.28 1772 39325 13866 3330896
Pancytopenia 4098.37 19.28 1463 39634 17357 3327405
Febrile neutropenia 2899.48 19.28 1139 39958 17836 3326926
Treatment failure 2758.92 19.28 839 40258 5685 3339077
Drug intolerance 2657.68 19.28 942 40155 10856 3333906
Arthralgia 2573.38 19.28 1508 39589 59353 3285409
Joint swelling 2538.65 19.28 1005 40092 16052 3328710
Pneumocystis jirovecii pneumonia 2537.20 19.28 697 40400 3093 3341669
Pneumonia 2532.46 19.28 1570 39527 68573 3276189
Nausea 2503.77 19.28 1974 39123 127671 3217091
Mucosal inflammation 2425.82 19.28 798 40299 7185 3337577
Pyrexia 2400.76 19.28 1602 39495 79513 3265249
Sepsis 2314.61 19.28 1139 39958 31234 3313528
Neutropenia 2044.25 19.28 1058 40039 32328 3312434
Interstitial lung disease 1952.72 19.28 788 40309 13228 3331534
Infection 1944.12 19.28 937 40160 24465 3320297
Synovitis 1891.26 19.28 476 40621 1369 3343393
Condition aggravated 1826.78 19.28 1037 40060 38196 3306566
Pain 1803.71 19.28 1282 39815 70275 3274487
Bone marrow failure 1733.99 19.28 631 40466 7856 3336906
Drug hypersensitivity 1662.86 19.28 944 40153 34736 3310026
Drug effect incomplete 1541.69 19.28 567 40530 7283 3337479
Vomiting 1531.28 19.28 1274 39823 88257 3256505
Toxicity to various agents 1524.68 19.28 986 40111 46068 3298694
Stomatitis 1495.36 19.28 621 40476 11231 3333531
Fatigue 1403.70 19.28 1311 39786 105929 3238833
Lymphoproliferative disorder 1391.75 19.28 319 40778 515 3344247
Off label use 1369.01 19.28 972 40125 53005 3291757
Thrombocytopenia 1360.44 19.28 826 40271 34442 3310320

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01BA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ANTIMETABOLITES
Folic acid analogues
ATC L04AX03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Other immunosuppressants
FDA EPC N0000175584 Folate Analog Metabolic Inhibitor
FDA MoA N0000000111 Folic Acid Metabolism Inhibitors
MeSH PA D000019 Abortifacient Agents
MeSH PA D000020 Abortifacient Agents, Nonsteroidal
MeSH PA D000963 Antimetabolites
MeSH PA D000964 Antimetabolites, Antineoplastic
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D003879 Dermatologic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005493 Folic Acid Antagonists
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D009676 Noxae
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D012102 Reproductive Control Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Psoriasis indication 9014002 DOID:8893
Rheumatoid arthritis indication 69896004 DOID:7148
Acute lymphoid leukemia indication 91857003 DOID:9952
Non-Hodgkin's lymphoma indication 118601006 DOID:8675
Burkitt's lymphoma indication 118617000 DOID:8584
Mycosis fungoides indication 118618005 DOID:8691
Malignant tumor of head and/or neck indication 255056009
Osteosarcoma of bone indication 307576001 DOID:3376
Malignant tumor of lung indication 363358000
Juvenile rheumatoid arthritis indication 410795001
Carcinoma of female breast indication 447782002
Gestational trophoblastic neoplasia indication 609519004 DOID:3590
Meningeal Leukemia indication
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Dehydration contraindication 34095006
Fibrosis of lung contraindication 51615001 DOID:3770
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Stomatitis contraindication 61170000 DOID:9637
Interstitial pneumonia contraindication 64667001 DOID:3082
Ulcerative colitis contraindication 64766004 DOID:8577
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:2527
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Bone marrow depression contraindication 307762000
Ascites contraindication 389026000
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Disorder of immune function contraindication 414029004
Pleural Effusions contraindication
Methotrexate Toxicity contraindication
Polymyositis off-label use 31384009
Vasculitis off-label use 31996006 DOID:865
Psoriasis with arthropathy off-label use 33339001 DOID:9008
Systemic lupus erythematosus off-label use 55464009 DOID:9074
Acute myeloid leukemia, disease off-label use 91861009 DOID:9119
Acute promyelocytic leukemia, FAB M3 off-label use 110004001 DOID:0060318
Wegener's granulomatosis off-label use 195353004 DOID:12132
Malignant tumor of urinary bladder off-label use 399326009 DOID:11054
Systemic Dermatomyositis off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.61 acidic
pKa2 5.15 acidic
pKa3 12.92 acidic
pKa4 5.73 Basic
pKa5 4.51 Basic
pKa6 1.39 Basic
pKa7 0.75 Basic
pKa8 0.08 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG/0.4ML (10MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 7744582 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
10MG/0.4ML (10MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
12.5MG/0.4ML (12.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
15MG/0.4ML (15MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 7744582 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
15MG/0.4ML (15MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
17.5MG/0.4ML (17.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
20MG/0.4ML (20MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 7744582 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
20MG/0.4ML (20MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
22.5MG/0.4ML (22.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
25MG/0.4ML (25MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 7744582 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
25MG/0.4ML (25MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
7.5MG/0.4ML (7.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Nov. 7, 2014 DISCN SOLUTION SUBCUTANEOUS RE44847 Aug. 10, 2019 SUBCUTANEOUS INJECTION OF METHOTREXATE
10MG/0.20ML (10MG/0.20ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
12.5MG/0.25ML (12.5MG/0.25ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
15MG/0.30ML (15MG/0.30ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
17.5MG/0.35ML (17.5MG/0.35ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
20MG/0.4ML (20MG/0.4ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
22.5MG/0.45ML (22.5MG/0.45ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
25MG/0.5ML (25MG/0.5ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
27.5MG/0.55ML (27.5MG/0.55ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 DISCN SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
30MG/0.6ML (30MG/0.6ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
7.5MG/0.15ML (7.5MG/0.15ML) RASUVO MEDAC PHARMA INC N205776 July 10, 2014 RX SOLUTION SUBCUTANEOUS 8664231 June 1, 2029 SUBCUTANEOUS INJECTION OF METHOTREXATE
10MG/0.4ML (10MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
10MG/0.4ML (10MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
10MG/0.4ML (10MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
10MG/0.4ML (10MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
12.5MG/0.4ML (12.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
12.5MG/0.4ML (12.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
12.5MG/0.4ML (12.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
12.5MG/0.4ML (12.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
15MG/0.4ML (15MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
15MG/0.4ML (15MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
15MG/0.4ML (15MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
15MG/0.4ML (15MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
17.5MG/0.4ML (17.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
17.5MG/0.4ML (17.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
17.5MG/0.4ML (17.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
17.5MG/0.4ML (17.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
20MG/0.4ML (20MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
20MG/0.4ML (20MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
20MG/0.4ML (20MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
20MG/0.4ML (20MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
22.5MG/0.4ML (22.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
22.5MG/0.4ML (22.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
22.5MG/0.4ML (22.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
22.5MG/0.4ML (22.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 March 24, 2016 RX SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
25MG/0.4ML (25MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
25MG/0.4ML (25MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
25MG/0.4ML (25MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
25MG/0.4ML (25MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Oct. 11, 2013 RX SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
7.5MG/0.4ML (7.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Nov. 7, 2014 DISCN SOLUTION SUBCUTANEOUS 8480631 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
7.5MG/0.4ML (7.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Nov. 7, 2014 DISCN SOLUTION SUBCUTANEOUS 8579865 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
7.5MG/0.4ML (7.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Nov. 7, 2014 DISCN SOLUTION SUBCUTANEOUS 8945063 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE
7.5MG/0.4ML (7.5MG/0.4ML) OTREXUP ANTARES PHARMA INC N204824 Nov. 7, 2014 DISCN SOLUTION SUBCUTANEOUS 9421333 March 19, 2030 SUBCUTANEOUS INJECTION OF METHOTREXATE

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 2MG BASE/ML XATMEP SILVERGATE PHARMS N208400 April 25, 2017 RX SOLUTION ORAL April 25, 2024 TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
EQ 2MG BASE/ML XATMEP SILVERGATE PHARMS N208400 April 25, 2017 RX SOLUTION ORAL April 25, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEOMOTHERAPY MAINTENANCE REGIMEN

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Dihydrofolate reductase Enzyme INHIBITOR Ki 8.92 IUPHAR DRUG LABEL
Multidrug resistance-associated protein 4 Transporter WOMBAT-PK
Multidrug resistance-associated protein 5 Transporter WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Canalicular multispecific organic anion transporter 1 Transporter WOMBAT-PK
Multidrug resistance protein 1 Transporter WOMBAT-PK
Thymidylate synthase Enzyme Ki 6.22 CHEMBL
Folylpolyglutamate synthase, mitochondrial Enzyme IC50 5.49 CHEMBL
Folate transporter 1 Unclassified Ki 5.46 CHEMBL
Folate receptor alpha Membrane receptor IC50 6.94 CHEMBL
Proton-coupled folate transporter Transporter IC50 6.92 CHEMBL
Folate receptor beta Membrane receptor IC50 6.97 CHEMBL
Dihydrofolate reductase Enzyme IC50 9 CHEMBL
Dihydrofolate reductase Enzyme IC50 8.89 CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase Enzyme IC50 8.85 CHEMBL
Bifunctional dihydrofolate reductase-thymidylate synthase Enzyme Ki 9.89 CHEMBL
Thymidylate synthase Enzyme IC50 5.74 CHEMBL
Dihydrofolate reductase Unclassified IC50 8.85 CHEMBL
Thymidylate synthase Enzyme IC50 4.40 CHEMBL
Dihydrofolate reductase Unclassified IC50 8.77 CHEMBL
Dihydrofolate reductase Enzyme Ki 10.14 CHEMBL
Dihydrofolate reductase Enzyme IC50 7.91 CHEMBL
Dihydrofolate reductase Unclassified Ki 10.68 CHEMBL
Thymidylate synthase Enzyme Ki 4.35 CHEMBL
Dihydrofolate reductase Enzyme Ki 5.41 CHEMBL
Dihydrofolate reductase Enzyme IC50 7.72 CHEMBL
Pteridine reductase 1 Enzyme Ki 7.41 CHEMBL

External reference:

scroll-->
IDSource
DB00563 DRUGBANK_ID
4815 IUPHAR_LIGAND_ID
4019828 VUID
N0000147916 NUI
C0025677 UMLSCUI
D00142 KEGG_DRUG
CHEMBL426 ChEMBL_ID
3IG1E710ZN UNII
7413-34-5 SECONDARY_CAS_RN
CHEMBL34259 ChEMBL_ID
4019828 VANDF
6851 RXNORM
387381009 SNOMEDCT_US
68887009 SNOMEDCT_US
d00060 MMSL
73119 MMSL
12261 MMSL
N0000007370 NDFRT
N0000147916 NDFRT
002644 NDDF
126941 PUBCHEM_CID
CHEMBL3244648 ChEMBL_ID
D008727 MESH_DESCRIPTOR_UI
926 INN_ID
CHEBI:50681 CHEBI
MTX PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Methotrexate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0054-4550 TABLET 2.50 mg ORAL ANDA 15 sections
Methotrexate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0054-8550 TABLET 2.50 mg ORAL ANDA 15 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0069-0146 INJECTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0069-0149 INJECTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0069-0204 INJECTION, SOLUTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9516 SOLUTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9517 SOLUTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9518 SOLUTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9519 SOLUTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9830 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 1 g INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0378-0014 TABLET 2.50 mg ORAL ANDA 15 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0555-0572 TABLET 2.50 mg ORAL ANDA 15 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0703-3671 INJECTION, SOLUTION 25 mg INTRA-ARTERIAL ANDA 12 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0703-3675 INJECTION, SOLUTION 25 mg INTRA-ARTERIAL ANDA 12 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 0703-3678 INJECTION, SOLUTION 25 mg INTRA-ARTERIAL ANDA 12 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 16729-277 INJECTION 25 mg INTRA-ARTERIAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 21695-111 TABLET 2.50 mg ORAL ANDA 13 sections
METHOTREXATE HUMAN PRESCRIPTION DRUG LABEL 1 42254-110 TABLET 2.50 mg ORAL NDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 42291-594 TABLET 2.50 mg ORAL ANDA 14 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 42605-034 SOLUTION 25 mg INTRA-ARTERIAL APPROVED DRUG PRODUCT MANUFACTURED UNDER CONTRACT 1 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 42605-035 SOLUTION 25 mg INTRA-ARTERIAL APPROVED DRUG PRODUCT MANUFACTURED UNDER CONTRACT 1 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 42605-036 SOLUTION 25 mg INTRA-ARTERIAL APPROVED DRUG PRODUCT MANUFACTURED UNDER CONTRACT 1 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 42605-037 SOLUTION 25 mg INTRA-ARTERIAL APPROVED DRUG PRODUCT MANUFACTURED UNDER CONTRACT 1 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 43063-439 TABLET 2.50 mg ORAL ANDA 15 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 47335-235 TABLET 2.50 mg ORAL ANDA 16 sections
METHOTREXATE HUMAN PRESCRIPTION DRUG LABEL 1 50090-0294 TABLET 2.50 mg ORAL NDA 16 sections
Methotrexate HUMAN PRESCRIPTION DRUG LABEL 1 51079-670 TABLET 2.50 mg ORAL ANDA 15 sections
Trexall HUMAN PRESCRIPTION DRUG LABEL 1 51285-366 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
Trexall HUMAN PRESCRIPTION DRUG LABEL 1 51285-367 TABLET, FILM COATED 7.50 mg ORAL ANDA 14 sections
Trexall HUMAN PRESCRIPTION DRUG LABEL 1 51285-368 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections